Cargando…

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are a common cause of bacteraemia in endemic countries and may be associated with high mortality; carbapenems are considered the drug of choice. Limited data suggest piperacillin-tazobactam could be equally effective. We aimed to c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ng, Tat Ming, Khong, Wendy X., Harris, Patrick N. A., De, Partha P., Chow, Angela, Tambyah, Paul A., Lye, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841518/ https://www.ncbi.nlm.nih.gov/pubmed/27104951 http://dx.doi.org/10.1371/journal.pone.0153696

Ejemplares similares

2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems
por: John, Reeba, et al.
Publicado: (2018)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

486 Meropenem and Piperacillin-tazobactam have Comparable Outcomes in Treatment of Bloodstream Infections Caused by Extended Spectrum Beta-lactamase Producing E.coli and Klebsiellae
por: Harris, Patrick, et al.
Publicado: (2014)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

Cefuroxime compared to piperacillin/tazobactam as empirical treatment of Escherichia coli bacteremia in a low Extended-spectrum beta-lactamase (ESBL) prevalence cohort
por: Thønnings, Sara, et al.
Publicado: (2019)

2432. Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit
por: Tucker, Kendall, et al.
Publicado: (2018)

Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae
por: Zha, Lei, et al.
Publicado: (2022)

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

Induction of plasmid-mediated AmpC β-lactamase DHA-1 by piperacillin/tazobactam and other β-lactams in Enterobacteriaceae
por: Akata, Kentaro, et al.
Publicado: (2019)

Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in Enterobacteriaceae Due to Narrow-Spectrum β-Lactamases as Well as Omp Mutation
por: Yang, Fengzhen, et al.
Publicado: (2022)

Piperacillin-tazobactam vs. carbapenem for treating blood stream infections due to extended spectrum β-lactamase producing bacteria: Systematic review and meta-analysis
por: Sfeir, Maroun, et al.
Publicado: (2017)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae
por: Zhang, Wei, et al.
Publicado: (2023)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Treatment of Piperacillin-Tazobactam–Nonsusceptible/Ceftriaxone-Susceptible Infections With Carbapenem Versus Carbapenem-Sparing Antimicrobials
por: Cao, John, et al.
Publicado: (2023)

Evaluation of a Carbapenem-Saving Strategy Using Empirical Combination Regimen of Piperacillin-Tazobactam and Amikacin in Hemato-Oncology Patients
por: Ko, Jae-Hoon, et al.
Publicado: (2019)

Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae
por: Katip, Wasan, et al.
Publicado: (2021)

Prevalence of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a teaching hospital in Ghana
por: Sampah, James, et al.
Publicado: (2023)

211. Disease burden of bacteremia with extended-spectrum beta-lactamase-producing or carbapenem-resistant Enterobacteriaceae in Korea
por: Mi Lee, Chan, et al.
Publicado: (2023)

646. Adapting the modified Carbapenem Inactivation Method to assess for possible beta-lactamase mediated resistance in Piperacillin-Tazobactam resistant/ Ceftriaxone susceptible Escherichia. coli and Klebsiella pneumoniae
por: Lawandi, Alexander, et al.
Publicado: (2020)

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli
por: Seo, Yu Bin, et al.
Publicado: (2017)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems
por: Walker, Kristy J., et al.
Publicado: (2018)

Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients
por: Lu, Brian, et al.
Publicado: (2023)

80. Pharmacoeconomic Analysis Comparing the Empiric Utilization of Cefepime Versus Piperacillin/tazobactam
por: Olmack, Kelsey, et al.
Publicado: (2020)

Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Fresh Produce
por: Pintor-Cora, Alberto, et al.
Publicado: (2021)

182. Piperacillin/tazobactam (P/T) versus meropenem (Mero) for treatment of extended-spectrum beta-lactamase (ESBL)-producing E.coli and K. pneumoniae bloodstream infections (BSIs)
por: Cox, Alexandra L, et al.
Publicado: (2023)

2436. Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections Due to Serratia, Citrobacter, or Enterobacter
por: Go, James, et al.
Publicado: (2018)

Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia
por: Alsaleh, Nada A, et al.
Publicado: (2020)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli
por: Rodríguez-Villodres, Ángel, et al.
Publicado: (2021)

1452. Is Carbapenem-Sparing Therapy as Effective as Carbapenems Against Extended-Spectrum β-Lactamase Producing Enterobacteriaceae in UTI?
por: Hyun, Jonghoon, et al.
Publicado: (2019)

Predicting Extended-Spectrum Beta-Lactamase and Carbapenem Resistance in Enterobacteriaceae Bacteremia: A Diagnostic Model Systematic Review and Meta-Analysis
por: Timbrook, Tristan T., et al.
Publicado: (2023)

Efficacy of Admission Screening for Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae
por: Lowe, Christopher F., et al.
Publicado: (2013)

838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
por: Stone, Tyler J, et al.
Publicado: (2020)

479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
por: Chin, Judy, et al.
Publicado: (2014)

Relating knowledge, attitude and practice of antibiotic use to extended-spectrum beta-lactamase-producing Enterobacteriaceae carriage: results of a cross-sectional community survey
por: Mo, Yin, et al.
Publicado: (2019)

1410. Novel Framework to Compare the Effectiveness of Tazobactam, Relebactam and Avibactam Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
por: Abodakpi, Henrietta, et al.
Publicado: (2018)

Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin/Tazobactam: Are Extended Infusions to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2015)

Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Bigseth, Robert Strengen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fva7nfe6vcosishamuua0ut7cq